Pseudoprogression of triple-hit diffuse large B-cell lymphoma following polatuzumab vedotin-based salvage therapy.

Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 25% of non-Hodgkin lymphoma cases [1]. Although often treatment-responsive, 30–40% of DLBCL patients develop refractory or relapsed ...